One hundred and seventy-seven stem cell apheresis procedures performed on 91 patients using the Fenwal CS 3000 Plus cell separator and 61 procedures performed on 37 patients using the Cobe Spectra cell separator were studied to compare the CD34 ؉ cell collection efficiencies (CE; the proportion of the total CD34 ؉ cell content in the blood volumes processed that is harvested) of the two machines. The absolute peripheral blood CD34
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recovery, and lower treatment-related mortality 3 and relapse rates. 2, 4 The quantity of CD34 ϩ cells collected and infused has a significant impact on rapidity of hematologic recovery 5 and outcome. 3 Since a cell separator is successful in collecting only a proportion of CD34 ϩ cells that pass through it during leukapheresis ('collection efficiency'), higher collection efficiency (CE) is desirable because it would result in the collection of a higher number of CD34 ϩ cells more rapidly. Higher leukocyte, hematocrit and albumin levels have been found to influence CE adversely. 6 We have shown recently that hematocrit does not affect CE of the Fenwal CS 3000 Plus cell separator. 7 A number of studies have compared CEs of different cell separators retrospectively and prospectively. [8] [9] [10] [11] [12] [13] The practice at our institution has been to use CS 3000 Plus cell separators almost exclusively for leukapheresis until recently when Cobe Spectra separators began to be employed regularly. This retrospective analysis was undertaken to compare the CEs of the two machines to see if there was a difference between them -and to determine the best way of employing different cell separators under normal clinical circumstances. The results may help other centers refine their practice and use of cell separators.
Patients and methods

Sample selection
One hundred and seventy-seven consecutive leukapheresis procedures performed on 91 patients (1-6 procedures per patient; median 1) from December 1999 to February 2001 using the Fenwal CS 3000 Plus cell separator (Baxter, Deerfield, IL, USA) were compared with 67 consecutive leukapheresis procedures performed on 37 patients (1-5 procedures per patient; median 1) from early March to early October 2001 using the Cobe Spectra cell separator (Gambro BCT, Lakewood, CO, USA).
Patient characteristics are shown in Table 1 . Most patients with malignant diseases had non-Hodgkin's lym- phoma, Hodgkin's disease, or multiple myeloma. The major difference between the two groups was the absence of normal donors in the CS 3000 Plus group and the absence of patients with non-malignant diseases in the Spectra group. The total leukocyte count in the CS 3000 Plus was slightly but statistically significantly higher. Availability of a peripheral blood CD34 ϩ cell count prior to apheresis on the day of apheresis (not routinely done prior to all apheresis procedures) was essential for inclusion in this analysis. Thus, not all patients apheresed during the specified time period were studied. For patients who were studied, not all procedures performed were studied.
Apheresis technique
All patients had rigid or semi-rigid two-lumen in-dwelling catheters inserted for apheresis. The blood flow rate used for apheresis was 85 ml/min for CS 3000 Plus and 70-100 ml/min for Spectra. The majority of the Spectra procedures was performed using the mononuclear cell collection protocol (Version 4.7). Usually 15 l blood was processed over approximately 3 h. All patients provided informed consent for the procedure, and all experimental or research protocols were approved by the institutional review board.
Flow cytometry
CD34
ϩ cells were enumerated using standard techniques 14 on the peripheral blood prior to leukapheresis and on the apheresis product prior to processing and cryopreservation.
Data analysis
The CD34 ϩ cell CE was the proportion (expressed as %) of the total CD34 ϩ cells processed (ie passing through the cell separator) that was harvested, and was calculated as follows:
{Total number of CD34 ϩ cells collected ϫ 10
Ϫ4
}/{absolute peripheral blood CD34 ϩ cell count per l ϫ blood volume processed (l)}.
Statistical methods
Regression analysis was used to assess correlation between the absolute peripheral blood CD34 ϩ cell count and the total number of CD34 ϩ cells collected to ensure the technical adequacy of the apheresis procedures and validity of the study analyses. Regression analysis was also employed to assess the correlation between the leukocyte count and CE, and the peripheral blood CD34 ϩ cell count and CE; separately for each type of machine. The 2 test was used to compare categorical variables and the Wilcoxon ranksum test was used to compare continuous variables. Finally, multivariate regression analysis was used to determine which of the following factors influenced CE independently: leukocyte count, peripheral blood CD34 ϩ cell count, and the machine used.
Results
The per cent mononuclear cell content was significantly higher for collections performed on the CS 3000 ( Table 2 ). The total number of CD34 ϩ cells collected and the CD34 ϩ cell yield per kg (per apheresis) were comparable for the two machines (Table 2 ). It is noteworthy that while the medians for both these parameters are substantially different (and are higher for the Spectra), the ranges are very wide making the overall yields not significantly different.
Collection efficiency
As Table 3 shows, CE was significantly higher with the Spectra (median 45.7%, range 9.8-98.6%) than the CS 3000 Plus (median 30.3%, range 1.7-89.3%; P Ͻ 0.00001).
The superiority of the Spectra in terms of higher CE was 565 Table 2 Comparison of the harvested products (median, range) clear at total leukocyte count levels of Ͻ20 ϫ 10 9 /l and Ͼ50 ϫ 10 9 /l, whereas it was only of borderline significance at leukocyte counts of 20-50 ϫ 10 9 /l. The CE of CS 3000 Plus declined with increasing leukocyte counts as reported previously 6 -the difference being most marked for counts Ͼ50 ϫ 10 9 /l. The CE of Spectra declined when the leukocyte count exceeded 20 ϫ 10 9 /l, but there was no further decline in CE with increasing leukocyte counts.
Similarly, the CE of CS 3000 Plus declined with increasing absolute peripheral blood CD34 counts with the most marked decline with counts Ͼ50/l. The CE of Spectra also declined when the absolute peripheral blood CD34 count exceeded 50/l.
No clear correlation emerged between CE and the total leukocyte count for the Spectra (r 2 ϭ 0.02; P ϭ 0.25; Figure 1 ) whereas a modest negative correlation was seen between CE and the total leukocyte count for the CS 3000 Plus (r 2 ϭ 0.10; P ϭ 0.00001; Figure 2 ). A modest negative correlation emerged between CE and the total leukocyte count for the Spectra (r 2 ϭ 0.08; P ϭ 0.03; Figure 3 ) as well as the CS 3000 Plus (r 2 ϭ 0.07; P ϭ 0.0004; Figure 4 ). In multivariate regression analysis, the cell separator used (Spectra better; P Ͻ 0.0001), the total leukocyte count (lower better when analyzed as a continuous variable; P Ͻ 0.0001), and the peripheral blood CD34 ϩ cell count (lower better when analyzed as a continuous variable; P ϭ 0.035) affected CE.
Interestingly, CE of Spectra harvests improved significantly with the passage of time (P ϭ 0.01) -possibly reflecting increasing familiarity of the apheresis staff with the machine. The median CE for the first 24 procedures performed from March to June was 36.1% (range, 13.2-62.0%) and CE for the subsequent 37 procedures performed from July to early October was 54.4% (range, 9.8-98.6%).
Discussion
Our data show that the CD34 ϩ cell CE is significantly better with the Cobe Spectra cell separator than with the Fenwal CS 3000 Plus under the operating conditions described. This superiority holds true across different levels of total leukocyte counts and absolute peripheral blood CD34 ϩ cell counts.
It should be noted that the CS 3000 Plus machine was not used optimally. Lin et al 13 showed that increasing the flow rate beyond the recommended 50 ml/min decreased CE for mononuclear cells and the total number of mononuclear cells collected with CS 3000 Plus. Our procedures were performed at 85 ml/min -a rate in excess of that recommended by the manufacturer. Stroncek et al 8 obtained a much better CE with the CS 3000 Plus because they used the slower flow rate of 50 ml/min. However, the more rapid rate we used allowed 15 l blood to be processed in 3 h, which was the time period for which patients were harvested on the Spectra too. We could perhaps have improved the CE by slowing the flow rate which would have prolonged the time taken to perform a 15 l apheresis to 5 h. The faster flow rate enables a machine to be used twice in a day during a standard shift. A 15 l procedure at 50 ml/min would make the procedure cumbersome and difficult to tolerate, and would preclude the use of the machine for a second procedure on the same day.
On the other hand, the Spectra, when using the mononuclear cell collection protocol (version 4.7), can keep the CE constant at flow rates of 20-150 ml/min. 11 Maximizing CE is essential to collect as many CD34 ϩ cells as posible over a given number of apheresis procedures or to reach a given target with fewer apheresis procedures. In either case, the use of a machine with a higher CD34 ϩ CE is more cost-efficient.
Ford et al 6 have shown that CD34 ϩ CE declines with increasing peripheral blood leukocyte counts. Our analysis showed this to be the case with the CS 3000 Plus but not with the Spectra. We also found that CE declined with increasing absolute peripheral blood CD34 ϩ cell counts with both machines. The observation of lower CEs with higher leukocyte counts and higher absolute peripheral blood CD34 ϩ cell counts is not very relevant in practice because the technique for mobilization is usually dictated by the disease being treated and the patient or donor's marrow reserve. Thus, there is no control over the level of leukocyte counts at which the harvest will take place. Also, in patients with abundant CD34 ϩ cells in the blood, a lower CE is rarely of concern.
In any case, we wanted to ensure that the disparity in the CEs was a true reflection of the capabilities of the machines rather than a result of the slightly higher leukocyte count in the CS 3000 Plus group (Table 1 ). As Table 3 shows, while CD34 ϩ cell CE of both machines does drop with increasing leukocyte counts, the Spectra performs better across the range of leukocyte counts studied.
Based on these findings, we have now started utilizing the Spectra preferentially for stem cell apheresis under normal circumstances. In the event that there is no Spectra cell separator available, a CS 3000 Plus is used for apheresing patients whose total leukocyte count is under 50 ϫ 10 9/ l.
